SCHEMBL23682809

SCHEMBL23682809

CC(C)(C)C(=O)c1ccc(C(=O)C(C)(C)C)o1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.44
HDAC4 P56524 1/20 0.44
ELANE P08246 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
CETP P11597 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HTT P42858 2/20 0.33
KLK7 P49862 1/20 0.33
TSHR P16473 1/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
BLM P54132 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
FBP1 P09467 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2625474 0.86 KLK7 (0.50) L3MBTL1MAPTHSD17B10HTTKLK7
SCHEMBL16572488 0.85 HDAC4 (0.44) HDAC6HDAC4ELANEL3MBTL1KDM4E
SCHEMBL10293768 0.84 MITF (0.47) HDAC6HDAC4ELANEL3MBTL1CETP
SCHEMBL13152188 0.84 ALDH1A1 (0.48) MAPTPKMHTTTSHRALDH1A1
SCHEMBL21980706 0.84 ALDH1A1 (0.46) HTTKLK7ALDH1A1KDM4EMEN1
SCHEMBL13066253 0.81 NPC1 (0.44) HDAC6HDAC4L3MBTL1MAPTPKM
SCHEMBL24674188 0.81 ALDH1A1 (0.51) MAPTHSD17B10ALDH1A1KDM4ETDP1
SCHEMBL26054460 0.80 HDAC4 (0.33) HDAC6HDAC4ELANE
SCHEMBL20018323 0.78 HDAC4 (0.53) HDAC6HDAC4L3MBTL1MAPTPKM
SCHEMBL13543152 0.78 ALDH1A1 (0.60) HTTTSHRALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-09-14 US disclosed
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-09-14 US disclosed
US-20210228723-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE NEDD4, CBL, UBQLN2 HDAC6 1477/4885HDAC4 2054/4885ELANE 3548/4885
US-20210228723-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ZFX, F13B, GRN HDAC6 645/4885HDAC4 785/4885ELANE 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.